The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Kukushkin M.L.
Research Institute of General Pathology and Pathophysiology
Bakhtadze M.A.
Research Institute of General Pathology and Pathophysiology;
Pirogov Russian National Research Medical University;
Clinic of restorative medicine «Quality of Life»
Churyukanov M.V.
Sechenov First Moscow State Medical University;
Petrovsky National Research Center of Surgery
Azimova Yu.E.
Research Institute of General Pathology and Pathophysiology;
University’s Headache Clinic LLC
Efficacy and safety of metamizole sodium for pain syndrome in adults and children: a systematic review
Journal: Russian Journal of Pain. 2024;22(4): 65‑80
Views: 889
Downloaded: 62
To cite this article:
Kukushkin ML, Davydov OS, Bakhtadze MA, Churyukanov MV, Azimova YuE, Maslakov AS, Garusova MYu. Efficacy and safety of metamizole sodium for pain syndrome in adults and children: a systematic review. Russian Journal of Pain.
2024;22(4):65‑80. (In Russ.)
https://doi.org/10.17116/pain20242204165
To conduct a systematic review of data on efficacy and safety of metamizole sodium (MS) for pain syndrome in adults and children.
A systematic review was conducted. At the first stage, we reviewed available databases regarding efficacy and safety of MS for pain syndrome in adults and children compared to other analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). Analysis included 38 randomized clinical trials and 5435 patients (children over 3 years old and adults).
MS significantly reduces pain syndrome compared to placebo within 30-60 min after administration. VAS scores decrease by more than 50% in 70-100% of cases. Effectiveness of MS is not inferior to paracetamol, acetylsalicylic acid, diclofenac, ibuprofen, ketorolac, ketoprofen and parecoxib. Effectiveness of different forms of MS is similar. At the same time, parenteral MS provides longer pain control compared to oral forms. MS in postoperative period reduces the need for reserve analgesics, including opioids. Unlike other NSAIDs, MS does not lead to gastric erosions, peptic ulcers or gastrointestinal bleeding. There is no effect on blood clotting. MS has good tolerability and safety comparable to the most popular NSAIDs. The risk of adverse events is lower compared to opioid analgesics. No serious adverse events were registered.
MS is effective and safe in adolescents over 15 years old and adults with pain syndrome.
Keywords:
Authors:
Kukushkin M.L.
Research Institute of General Pathology and Pathophysiology
Bakhtadze M.A.
Research Institute of General Pathology and Pathophysiology;
Pirogov Russian National Research Medical University;
Clinic of restorative medicine «Quality of Life»
Churyukanov M.V.
Sechenov First Moscow State Medical University;
Petrovsky National Research Center of Surgery
Azimova Yu.E.
Research Institute of General Pathology and Pathophysiology;
University’s Headache Clinic LLC
Received:
26.09.2024
Accepted:
13.10.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.